Table 3. Pharmacokinetic parameters of MTX in rats after intragastrical administration of MTX (2 mg/kg; n=6, mean ± SD) with or without co-administration of multiple-dose WZC.
| Parameter | MTX | WZC (150 mg/kg) + MTX | WZC (450 mg/kg) + MTX |
|---|---|---|---|
| Tmax (h) | 0.5±0.18 | 0.89±0.52 | 1.39±0.83 |
| Cmax (μg/L) | 162.3±11.2 | 170.8±35 | 261±74.1* |
| t1/2 (h) | 5.7±3.54 | 5.34±1.02 | 4.49±1.17 |
| AUC(0–24 h) (μg·h/L) | 440.2±96.1 | 781.6±466 | 1,116±323.7** |
| CL/F (L/h/kg) | 4.65±1.12 | 3.06±1.3* | 1.86±0.46** |
| Vz/F (L/kg) | 40.5±34.4 | 24.8±12.3 | 12.6±5.9 |
*, P<0.05; **, P<0.01 indicate significant differences from the MTX group. MTX, methotrexate; WZC, Wuzhi capsule; AUC, area under the curve.